Celldex Therapeutics Inc.

It earns from research, development and licensing collaborations, such as fees and milestone or royalty payments, rather than from selling an approved product, since it has none. It has posted a loss every year on record, so this collaboration income does not cover its own costs, and it depends on financing from outside the business rather than income it generates itself.

Because it has no approved product, its scale depends on which candidates clear regulatory review rather than on production capacity or sales volume, so nothing it does converts into recorded revenue until that happens. CompanyGraph's data shows it funding research spending that is large relative to its income partly by growing its share count over several years, so it scales its capital base by issuing new shares rather than through revenue growth. This way of funding growth is common among a large group of other companies CompanyGraph maps as running the same kind of regulation-dependent business.

The company depends on outside contract research organizations to run its clinical trials and on contract development and manufacturing organizations for raw materials, drug production and future supply, including some single-source manufacturing relationships it states have no qualified alternative. It also depends on successful patient enrollment in trials, on regulatory approval, on protecting its intellectual property, on retaining key personnel, on raising outside capital, and on its research collaboration with Rockefeller University, which it identifies as generating most of its recorded revenue. CompanyGraph's mapping separately places it downstream of a small number of other industries, without naming them.

The company names one collaboration partner as a major customer, Rockefeller University, and describes the funding from that relationship as the source of most of its recorded revenue. CompanyGraph also maps it as sitting upstream of a number of other industries, meaning other kinds of companies draw on the sort of specialized research and development work it does, though none of those companies are individually named.

CompanyGraph maps this company as running the same kind of system as a large number of other companies, where a regulatory decision rather than production or sales determines when revenue can begin, so the basic shape of its business is not structurally uncommon. The company itself states that its specific antibody programs and in-house development experience are what set it apart, including describing one candidate as a potential best-in-class treatment, but CompanyGraph has no independent way to confirm whether competitors could replicate that specific work.

The company states that its growth is limited by the amount of financial resources it can raise, by its management team's limited experience running a larger organization, by its ability to recruit and train qualified staff, by how quickly patients enroll in its trials, by whether regulators approve its candidates, and by securing more than one manufacturing source for each candidate. It states that if it cannot raise enough additional funding, it may have to slow, reduce or stop its development and operating work.

The company discloses that some of its manufacturing relationships are with a single source for which it states no qualified alternative exists, and that one academic research collaboration accounts for most of its recorded revenue. It also names its own need for additional capital, and unresolved obligations tied to a past corporate merger and settlement, as the risks it lists first in its own filings.

The company names needing additional capital, obligations tied to a past merger and settlement, and completing research and development as the pressures it emphasizes first, ahead of the pressures common to this kind of business: regulatory approval, extended regulatory review, disruption at the government bodies that grant approval, clinical trial execution, and the behavior of collaborators and competitors. Some of its manufacturing relationships sit outside the United States, so it is also exposed to conditions beyond domestic borders.